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Haig H. Kazazian, Jr.2,*It is a great pleasure and privilege to introduce StuartOrkin, the 2014 recipient of the William Allan Award,
the highest honor of our society. Orkin’s research is un-
matched for its cumulative impact on the genetic basis of
blood diseases and fundamental aspects of mammalian
development. His work is a paradigm for the application
of molecular genetics to medicine.
Stu was born to native New Yorkers and grew up in
Manhattan. His father was a urologist who made house
calls. When Stu was in the fourth grade, the family moved
to Riverdale, where he attended a private boys’ school. At
Riverdale, he had a chemistry teacher who stimulated
him to attend the Massachusetts Institute of Technology
(MIT). After flirting with physics, he quickly learned that
MIT had many physics whizzes, so after Salvador Luria’s
biology course on early molecular genetics, he decided to
pursue biology. Stu then began attending Harvard Medical
School in 1967, and around 1970 he took a year of research
with John Littlefield to do somatic cell genetics. After the
NIH paid for his fourth year in medical school, he did an
internship at Boston Children’s Hospital. He then went
to the NIH to work with Phil Leder, an esteemed molecular
geneticist. What a great deal and terrific mentor he had!
With Leder, Orkin learned pre-cloning molecular biology.
Around this time, I met him for the first time and was quite
impressed. After his time at the NIH, he returned to Boston
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at the time, offered Orkin the opportunity to start his
own lab while he was still a hematology-oncology fellow.
The rest is history!
Personally, he met his wonderful wife, Roz, while both
were in college. They’ve been married 44 years and have
one daughter and two grandkids, ages 5 and 3.
I had the pleasure of collaborating with Stu in the early
1980s on the characterization of mutations causing b-thal-
assemia in various ethnic groups—Mediterraneans, Asian
Indians, and Chinese, among others. Stylianos Antonara-
kis, then a fellow, found in the b-globin gene cluster
a number of new restriction-fragment-length poly-
morphisms that produced nine major haplotypes. Had
different b-thalassemia mutations landed on different
haplotypes? We picked mutant b-globin genes, which Stu
then cloned and sequenced. Indeed, among nine different
Mediterranean haplotypes with b-thalassemia, there were
eight different mutations affecting transcription, RNA
splicing, and translation. What fun this was! Stu would
call almost daily with new information! He stayed at our
home as we finished the first paper in late 1981. Over the
next 5 years, we wrote 25 other papers covering b-thalas-
semiamutations in other ethnic groups. But this molecular
characterization of a Mendelian disease was just the first of
many breakthroughs for Orkin.
In 1986, he used the Xp21 deletion found by Uta
Francke and help from Tony Monaco and Lou Kunkel to
carry out the first positional cloning of any gene: CYBB,
the gene mutated in chronic granulomatous disease.
In 1989, Orkin found the first transcriptional regulator
of hematopoiesis, GATA-1. He followed that with the dis-
covery of many other transcription factors important for
blood cell development. Orkin then used gene targeting
in mice to determine in vivo roles for many of these tran-
scriptional regulators in blood stem cells or hematopoietic
lineages. Because of this work, Orkin is considered the
‘‘father’’ of molecular hematopoiesis.
Recently, Orkin has made another stunning discovery
that represents the first inroad into the most important
unsolved area in hemoglobin disorders: regulation of the
switch from fetal to adult hemoglobin. He found that
repressing Bcl11a leads to increased fetal hemoglobin and
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of sickle cell anemia. Orkin might now have a rational
approach to curing sickle cell anemia and b-thalassemia
by increasing fetal hemoglobin, a holy grail in hematology
for many years.
Stu has received many honors, including election to the
Institute of Medicine, the American Academy of Arts and
Sciences, and the National Academy of Science. Among
his many awards is the 2013 Kovalenko Medal of the
National Academy of Science, awarded for important
contributions to medical science. He has published overThe Ame500 scientific papers, including 225 with greater than 100
citations. His mentoring of many graduate students and
postdocs is legendary. Among his distinguished mentees
are David Ginsburg, Leonard Zon, Nancy Andrews, and
my ex-colleagues at Penn Celeste Simon, Gerd Blobel, and
MitchWeiss. A physician-scientist working between funda-
mental biology and human disease, Orkin has contributed
enormously to the development of molecular medicine
and genetics. These accomplishments are highly worthy
of recognition with the 2014 Allan Award to Stuart Orkin.rican Journal of Human Genetics 96, 352–353, March 5, 2015 353
